Company Performance Metrics
Orly Weinreb: CEO- Tali Fishman: CTO
GlaucoPharm is developing TG-46, a novel topical treatment for glaucoma. TG-46 is useful for the treatment of diseases modulated by the Pyrimidinergic receptor P2Y6, such lowering intraocular pressure (IOP) and there by Glaucoma. The P2Y6 receptor has been identified in Trabecular Meshwork cells (TM), an area of tissue in the eye that is
responsible for draining the aqueous humor.
TG-46 shows evidence of a novel mechanism of action, potential alternative to first line drugs, It binds tightly and selectively to P2Y6R. TG-46 reduces IOP by 45%, compared to the 25-35% of current drugs in the market. It is highly chemically and enzymatically stable (duration of action is higher than 3.5 hours). Its synthesis is facile and result in good yields. Preliminary data show that it does not exert several side-effects typical current drugs such as-effects on the cardiovascular system’ on the pupils or iris pigmentation.
